Metabolic activity assessment of cardiac angiosarcoma by 18FDG PET-CT

Bilski, Marek; Kamiński, Grzegorz; Dziuk, Mirosław

doi:10.5603/nmr.2012.0015

Cited by 8 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positron emission tomography/CT has advantages in non-invasively characterizing cardiac tumors and disease staging, scarce case reports have described the use of FDG PET-CT in differentiating the benign and malignant mass, metastatic workup, preoperative staging, and assessment of response to treatment in primary cardiac angiosarcomas ( 16 – 19 ). Rahbar et al ( 20 ) in their study of various cardiac tumors proposed that malignancy was determined with a sensitivity of 100% and specificity of 86% (accuracy, 96%) after a cutoff with high sensitivity (SUVmax of 3.5) was chosen to avoid false-negatives.…”

Section: Discussionmentioning

confidence: 99%

Case report: Primary cardiac angiosarcoma with multiple metastases

Lan

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

This reports outlines a rare case of primary right atrial angiosarcoma with multiple metastases. Multimodality imaging and histopathology confirmed the diagnosis of primary cardiac angiosarcoma and multiple metastases. We present the details of the presentation, multimodality imaging findings, and clinical management. The patient was followed up by cardiac MRI (CMRI) 2 months after therapy, the cardiac tumor and pulmonary metastases decreased markedly. Up to now, the patient has undergone four cycles of chemotherapy and immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report: Primary cardiac angiosarcoma with multiple metastases

Lan

2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Therefore, it is vital to ascertain the precise extent of the primary lesion, to detect local recurrence and distant metastases for appropriate therapy management 4. A review of published literature have shown mainly the use of positron emission tomography (PET) with tracer 2-deoxy-2-[ 18 F]-fluoro-D-glucose ( 18 F-FDG PET-CT) in cardiac angiosarcoma 1–3 6–8. Around 20 cases have been reported in literature.…”

Section: Introductionmentioning

confidence: 99%

Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3′-deoxy-3′[⁽¹⁸⁾F]-fluorothymidine, [⁽¹⁸⁾F]-FLT imaging and early response evaluation

Kairemo

Subbiah²

2019

BMJ Case Rep

View full text Add to dashboard Cite

Primary cardiac angiosarcoma, the most common primary cardiac sarcoma has an incidence ranging from 0.001% to 0.028% in autopsy reports with around 200 cases reported in literature. Since a diagnosis of cardiac angiosarcoma portends a poor prognosis, it is vital to ascertain the precise extent of the lesions for follow-up. Imaging with positron emission tomography (PET) tracer 2-deoxy-2-[18F]-fluoro-D-glucose in cardiac angiosarcoma is challenging as myocardium takes up glucose and delineation of tumour becomes difficult. Cell proliferation rate in normal cardiac muscular tissue is low whereas cardiac tumours display a higher proliferation rate. This aspect could be exploited by use of 3′-deoxy-3′[(18)F]-fluorothymidine positron emission tomography (18F-FLT PET/CT] in cardiac tumours where the cell proliferation could be measured. Herein, we imaged an index case of cardiac angiosarcoma using 18F-FLT PET/CT and report the findings.

show abstract